Keyphrases
Pharmacokinetics
54%
Voriconazole
34%
Posaconazole
33%
Therapeutic Drug Monitoring
26%
Critically Ill Patients
26%
Invasive Aspergillosis
17%
Pharmacodynamics
15%
Target Attainment
14%
Liposomal Amphotericin B
14%
Antifungal Drugs
13%
Micafungin
12%
Fluconazole
12%
Anidulafungin
12%
Caspofungin
12%
Antifungal Therapy
12%
Oncology Patients
12%
Azoles
12%
Isavuconazole
12%
Aspergillus Fumigatus
11%
Population Pharmacokinetics
11%
Plasma Concentration
11%
Dosing Regimen
10%
Morbid Obesity
10%
COVID-19-associated Pulmonary Aspergillosis
10%
Drug Interactions
10%
Pharmacokinetic Study
10%
Intensive Care Unit Patients
9%
Invasive Fungal Disease
9%
Tacrolimus
9%
Renal Function
8%
Dried Blood Spots
8%
Invasive Pulmonary Aspergillosis
8%
Obesity
8%
Obese Men
8%
Flucloxacillin
8%
COVID-19
8%
Population Pharmacokinetic Model
8%
Invasive Fungal Infection
8%
Minimum Inhibitory Concentration
8%
Antifungal Prophylaxis
8%
Trough Concentration
8%
Pediatric Patients
8%
Azole Antifungals
7%
Non-obese
7%
Azole-resistant
7%
Patients with Hematological Malignancies
7%
Aspergillus
7%
High Dose
7%
Renal Transplant Recipients
7%
Total Body Weight
7%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Antifungal Agent
35%
Posaconazole
32%
Voriconazole
31%
Invasive Aspergillosis
25%
Infection
23%
Therapeutic Drug Monitoring
22%
Pharmacodynamics
22%
Pyrrole
20%
Disease
18%
Amphotericin B
15%
Aspergillus fumigatus
13%
Fluconazole
12%
Caspofungin
12%
Anidulafungin
12%
Micafungin
11%
Normal Human
10%
Lung Aspergillosis
10%
Isavuconazole
9%
Antifungal Therapy
9%
Tacrolimus
9%
Flucloxacillin
8%
Systemic Mycosis
8%
Mycosis
7%
Vancomycin
7%
Ciprofloxacin
6%
Aspergillus
6%
Aspergillosis
6%
Minimum Inhibitory Concentration
6%
Pyrrole Derivative
6%
Infectious Agent
6%
Drug-Drug Interaction
6%
Itraconazole
6%
Volume of Distribution
5%
Malignant Neoplasm
5%
Hematologic Malignancy
5%
Mucosa Inflammation
5%
Triazole
5%
Ultra High Performance Liquid Chromatography
5%
Antiinfective Agent
5%
